RSV usually only has mild symptoms, but it can lead to breathing problems in the most vulnerable infants. The vaccine is ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also ...

Real-world analysis of the first season of vaccination against RSV has shown a dramatic impact on hospitalisation.

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Study to ...

Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, highlighting the need for targeted outreach programs.

The US FDA approved an RSV vaccine called Arexvy. How effective is it, when will it be available, and who can take it? CNN Medical Analyst Dr. Leana Wen explains.

The NHS is urging newly eligible pregnant mothers that “now is the time to act” and get the RSV vaccine to protect their baby ahead of ...

RSV vaccines are on the way: Here's what the CDC says about them. In the fall, Pfizer said results from a Phase 3 clinical trial showed its vaccine protected infants when given to pregnant ...

A vaccine to protect against severe cases of Respiratory Syncytial Virus could roll out as early as August. Pfizer has developed RSVpreF, a vaccine to prevent severe cases of RSV, and the Food and ...

Moderna's respiratory syncytial virus, or RSV, vaccine for older adults was about 84% effective at preventing serious illness, according to data from a late-stage trial published Tuesday. Adult ...